Chemical Structure (Tranexamic 01)
Tranexamic Acid Tablet
Product Images NDC 69918-301
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Tranexamic Acid (NDC 69918-301). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Nordic Pharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1 (Tranexamic 02)
This is a graph presenting the mean menstrual blood loss (in mL) for different treatments in 3-cycle and 6-cycle studies. The treatments include Tranexamic acid (3900 mg/day) and a placebo. The graph shows a decreasing trend in mean menstrual blood loss for Tranexamic acid treatment compared to the placebo. The x-axis shows different treatment periods, while the y-axis shows the mean menstrual blood loss in mL.*
Principal Display Panel (30 Tablet Bottle Label)
This text is a product label for "Tranexamic Acid USP" tablets, which are manufactured by Amring Pharmaceuticals Inc. These tablets are for prescription use only and should be taken three times daily (3.9 g/day) during menstruation. Each tablet contains 650 mg of tranexamic acid. The label provides specific storage instructions, advising the tablets to be kept at 25°C (77°F), with excursions permitted between 15°-30°C (59°-86°F). For complete usage and prescribing information, the package insert should be consulted.*
Company Label (Tranexamic 04)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
